| DIRECT COMPETITOR COMPARISON | |
| NBY | CBST | PFE | SNN | Industry | | Market Cap: | 45.85M | 962.48M | 147.27B | 8.57B | 161.24M | | Employees: | 31 | 554 | 81,800 | 9,757 | 103 | | Qtrly Rev Growth (yoy): | 102.50% | 27.70% | -2.90% | -1.60% | 20.50% | | Revenue (ttm): | 10.39M | 526.58M | 45.82B | 3.67B | 46.74M | | Gross Margin (ttm): | 27.39% | 51.53% | 86.61% | 74.09% | 68.58% | | EBITDA (ttm): | -1.94M | 157.04M | 21.31B | 1.09B | -7.12M | | Oper Margins (ttm): | -22.08% | 27.60% | 37.42% | 22.42% | 2.25% | | Net Income (ttm): | -2.25M | 193.33M | 8.09B | 461.00M | N/A | | EPS (ttm): | -0.103 | 2.732 | 1.204 | 2.60 | -0.17 | | P/E (ttm): | N/A | 6.08 | 15.16 | 18.66 | 17.12 | | PEG (5 yr expected): | N/A | 0.58 | 5.88 | 1.51 | 1.04 | | P/S (ttm): | 4.41 | 1.83 | 3.21 | 2.34 | 4.17 |
|
| CBST = Cubist Pharmaceuticals Inc. | | PFE = Pfizer Inc. | | SNN = Smith & Nephew plc | | Industry = Drug Manufacturers - Other | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.50 | 0.00% | 57.19B | 12.32 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 46.92 | 0.00% | 13.57B | 15.70 | | Genzyme Corp. | GENZ | 51.07 | 0.00% | 13.55B | 29.12 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.56 | 0.00% | 41.90B | 18.00 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.95 | 0.00% | 8.91B | 1019.39 | | Teva Pharmaceutical Industries Limited | TEVA | 52.88 | 0.00% | 46.59B | 48.38 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 36.96 | 0.00% | 3.92B | 19.05 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.95 | 0.00% | 2.97B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.01 | 0.00% | 5.50B | 110.49 | | Pfizer Inc. | PFE | 18.25 | 0.00% | 147.27B | 15.16 | | Johnson & Johnson | JNJ | 62.89 | 0.00% | 173.52B | 13.73 | | GlaxoSmithKline plc | GSK | 42.26 | 0.00% | 107.13B | 13.42 | | Sanofi-Aventis | SNY | 38.43 | 0.00% | 100.35B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.38 | 0.00% | 125.78B | 16.58 | | RHHBY.PK | 41.46 | 0.00% | N/A | N/A | | AstraZeneca plc | AZN | 45.29 | 0.00% | 65.67B | 9.09 | | Abbott Laboratories | ABT | 54.08 | 0.00% | 83.65B | 14.65 | | Bristol-Myers Squibb Co. | BMY | 25.38 | 0.00% | 50.28B | 13.13 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | PFE | | UPDATE - Takeda: eyeing M&A for generics in emerging markets
Mon 3:39am -
at Reuters | | • | PFE | | Bayer starts Phase III study for Alzheimer test
Mon 3:00am -
at Reuters | | • | PFE | | 12 Years Of Patent Protection For Biologics Based Research And Development Creates Buying Opportunity In Biotech Stocks
Sat, Nov 28 -
Wall Street Transcript | | • | PFE | | The fall of the world's best-selling drug
Fri, Nov 27 -
at FT.com | | • | PFE | | This Week's 5 Dumbest Stock Moves
Fri, Nov 27 -
at Motley Fool | | • | CBST | | CUBIST PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
Mon, Nov 23 -
EDGAR Online | | • | SNN | | [$$] A Time to Fight, a Time to Heal
Sat, Nov 21 -
at Barrons.com | | • | SNN | | Smith & Nephew wins Department of Defense contract
Fri, Nov 20 -
at bizjournals.com | | • | SNN | | Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries
Fri, Nov 20 -
PR Newswire | | • | SNN | | Smith & Nephew Supports New CPT Code for Multi-Layer Compression Bandaging Systems
Thu, Nov 19 -
PR Newswire | | • | CBST | | Biotech Stocks for a Possible Year-End Rally
Wed, Nov 18 -
at Seeking Alpha | | • | SNN | | Smith & Nephew Endoscopy Announces Availability of TRUCLEAR(TM) Hysteroscopic Morcellator at the AAGL Annual Meeting
Tue, Nov 17 -
PR Newswire | | • | CBST | | Options Boil on Biotech Buyout Rumors
Thu, Nov 12 -
at CNBC | | • | CBST | | Counting On Cubist To Gain A Bit More
Thu, Nov 12 -
at Forbes.com | | • | CBST | | The Boston Globe names Cubist to Globe 100's Top Places to Work '09
Mon, Nov 9 -
Business Wire | | • | CBST | | Alnylam slips on Q3 loss, cautious outlook
Thu, Nov 5 -
at bizjournals.com | | | All Headlines for these symbols... |
|
|
|
1.48% Nasdaq 0.00%
Competitors
